04:29 , Jan 11, 2019 |  BC Innovations  |  Product R&D

Biomarkers’ road less traveled

FDA’s draft guidance on biomarker qualification provides welcome codification of the regulatory path. But the amount of data required may remain beyond the reach of most companies, strengthening the importance of consortia. The guidance ,...
18:15 , Feb 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Nucleic acids Modifying the seed region of hepatocyte-targeted siRNAs could help develop therapies with minimal hepatic toxicity. The approach involves generating siRNA guide strands containing a glycol nucleic acid (GNA) nucleotide in the seed...
07:00 , Jul 14, 2016 |  BC Innovations  |  Tools & Techniques

Cryo-EM a river

Once considered the poor cousin in structural biology, cryo-electron microscopy (cryo-EM) has found new favor in industry, after technical improvements have broken barriers in molecular size and resolution, resulting in floods of data that can...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

bioMerieux sales and marketing update

bioMerieux launched its Vidas C. difficile GDH immunoassay to diagnose Clostridium difficile infections. The test detects the enzyme glutamate dehydrogenase antigen (GDH), which is produced by C. difficile. The test has CE Mark approval and...
07:00 , Apr 4, 2013 |  BC Innovations  |  Targets & Mechanisms

Glutamine metabolism drives PDAC

Researchers at the Dana-Farber Cancer Institute have identified a glutamine metabolism pathway that is activated by oncogenic K-Ras in pancreatic cancers. 1 Moreover, the team found three different enzyme targets within the pathway that could...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Clinical News

ImmunoCard C regulatory update

FDA approved Meridian's ImmunoCard C. difficile GDH test for Clostridium difficile infection. The test detects the presence of the C. difficile common antigen glutamate dehydrogenase (GDH) and is available worldwide. Meridian Bioscience Inc. (NASDAQ:VIVO), Cincinnati,...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Meridian Bioscience sales and marketing update

Meridian launched its ImmunoCard C. difficile test in Europe to detect Clostridium difficile infection (CDI). The assay detects glutamate dehydrogenase in stool samples. Meridian Bioscience Inc. (NASDAQ:VIVO), Cincinnati, Ohio   Business: Diagnostic  ...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Premier C regulatory update

FDA approved Meridian's Premier C. difficile GDH assay to detect Clostridium difficile infection. The test detects an antigen produced by toxigenic and non-toxigenic forms of C. difficile and is already marketed in Europe. Meridian Bioscience...
07:00 , May 13, 2010 |  BC Innovations  |  Targets & Mechanisms

Sending ammonia signals

Ammonia has long been viewed as a toxic cellular by-product of glutamine metabolism that has little or no functionality. New findings by a group at Pfizer Inc. now suggest this may not always be the...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Extraneal regulatory update

FDA approved a boxed warning to the label of Extraneal peritoneal dialysis solution to warn of dangerous drug-device interaction. The boxed warning states that blood glucose measurement in patients receiving Extraneal must be done with...